Trial Profile
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study of Cabozantinib (XL184) in Subjects With Radioiodine-Refractory Differentiated Thyroid Cancer Who Have Progressed After Prior Vascular Endothelial Growth Factor Receptor (VEGFR) -Targeted Therapy
Status:
Active, no longer recruiting
Phase of Trial:
Phase III
Latest Information Update: 12 Sep 2023
Price :
$35
*
At a glance
- Drugs Cabozantinib (Primary)
- Indications Carcinoma; Thyroid cancer
- Focus Registrational; Therapeutic Use
- Acronyms COSMIC-311
- Sponsors Exelixis
- 18 Aug 2023 This trial has been discontinued in Austria, according to the European Clinical Trials Database record.
- 16 May 2023 Planned End Date changed from 1 Dec 2022 to 1 Dec 2023.
- 04 Mar 2023 Results assessing population pharmacokinetic (PopPK) and exposure-response analysis of COSMIC-311 study published in the Clinical Pharmacokinetics